Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate.

Hill A, Breyer S, Geissler S, Mier W, Haberkorn U, Weigandt M, Mäder K.

J Control Release. 2013 May 28;168(1):77-87. doi: 10.1016/j.jconrel.2013.03.005. Epub 2013 Mar 15.

PMID:
23499716
2.

In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps.

Hill A, Geissler S, Meyring M, Hecht S, Weigandt M, Mäder K.

Int J Pharm. 2013 Jul 15;451(1-2):57-66. doi: 10.1016/j.ijpharm.2013.04.060. Epub 2013 Apr 26.

PMID:
23628403
3.

Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics.

Hill A, Geissler S, Weigandt M, Mäder K.

J Control Release. 2012 Mar 28;158(3):403-12. doi: 10.1016/j.jconrel.2011.12.005. Epub 2011 Dec 14.

PMID:
22198270
4.

Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.

Xu Y, Wang Y, Li XM, Huang Q, Chen W, Liu R, Chen B, Wei P.

Drug Dev Ind Pharm. 2014 Jul;40(7):972-9. doi: 10.3109/03639045.2013.794828. Epub 2013 May 21.

PMID:
23692349
5.

Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS).

Friedrich I, Reichl S, Müller-Goymann CC.

Int J Pharm. 2005 Nov 23;305(1-2):167-75. Epub 2005 Oct 19.

PMID:
16242276
6.

Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.

Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, Zhang L, Zhang K, Zhang Y, Tang X.

Int J Pharm. 2014 Dec 30;477(1-2):88-95. doi: 10.1016/j.ijpharm.2014.10.025. Epub 2014 Oct 14.

PMID:
25455766
7.

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P.

Adv Drug Deliv Rev. 2007 Jul 10;59(6):419-26. Epub 2007 May 3.

PMID:
17566595
8.

Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.

Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W.

Int J Pharm. 2008 May 1;355(1-2):321-7. doi: 10.1016/j.ijpharm.2007.12.016. Epub 2007 Dec 23.

PMID:
18242896
9.

Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies.

Gullapalli R, Wong A, Brigham E, Kwong G, Wadsworth A, Willits C, Quinn K, Goldbach E, Samant B.

Drug Deliv. 2012 Jun-Jul;19(5):239-46. doi: 10.3109/10717544.2012.691121. Epub 2012 Jun 1.

PMID:
22656673
10.

Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.

Yadav SK, Mishra S, Mishra B.

AAPS PharmSciTech. 2012 Dec;13(4):1031-44. doi: 10.1208/s12249-012-9833-0. Epub 2012 Aug 15.

11.

Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery.

Liu Y, Zhang D, Duan C, Jia L, Xie P, Zheng D, Wang F, Liu G, Hao L, Zhang X, Zhang Q.

J Microencapsul. 2012;29(2):194-203. doi: 10.3109/02652048.2011.642015. Epub 2011 Dec 16.

PMID:
22172025
12.

In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size.

Liu G, Zhang D, Jiao Y, Guo H, Zheng D, Jia L, Duan C, Liu Y, Tian X, Shen J, Li C, Zhang Q, Lou H.

Colloids Surf B Biointerfaces. 2013 Feb 1;102:620-6. doi: 10.1016/j.colsurfb.2012.09.006. Epub 2012 Sep 11.

PMID:
23107940
13.

Development of an oral push-pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles.

Zhao Z, Wu C, Zhao Y, Hao Y, Liu Y, Zhao W.

Int J Nanomedicine. 2015 Mar 3;10:1691-701. doi: 10.2147/IJN.S76755. eCollection 2015.

14.

In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain.

Lesser GJ, Grossman SA, Leong KW, Lo H, Eller S.

Pain. 1996 May-Jun;65(2-3):265-72.

PMID:
8826516
15.

The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.

McClelland GA, Sutton SC, Engle K, Zentner GM.

Pharm Res. 1991 Jan;8(1):88-92.

PMID:
2014214
16.

Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation.

Liu D, Yu S, Zhu Z, Lyu C, Bai C, Ge H, Yang X, Pan W.

Int J Pharm. 2014 Nov 20;475(1-2):496-503. doi: 10.1016/j.ijpharm.2014.09.008. Epub 2014 Sep 8.

PMID:
25219321
18.

Distribution of [3H]dexamethasone in rat subcutaneous tissue after delivery from osmotic pumps.

Moussy Y, Hersh L, Dungel P.

Biotechnol Prog. 2006 May-Jun;22(3):819-24.

PMID:
16739966
19.

Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application.

Mudgil M, Pawar PK.

Sci Pharm. 2013 Jun;81(2):591-606. doi: 10.3797/scipharm.1204-16. Epub 2013 Feb 4.

20.

Stability of nanosuspensions in drug delivery.

Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D.

J Control Release. 2013 Dec 28;172(3):1126-41. doi: 10.1016/j.jconrel.2013.08.006. Epub 2013 Aug 14. Review.

PMID:
23954372
Items per page

Supplemental Content

Write to the Help Desk